A Study of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00002439|
Recruitment Status : Completed
First Posted : August 31, 2001
Last Update Posted : June 24, 2005
Anderson Clinical Research
Information provided by:
NIH AIDS Clinical Trials Information Service
The purpose of this study is to see if ALRT1057 gel is safe and effective in treating Kaposi's sarcoma (KS) when applied to skin .
|Condition or disease||Intervention/treatment|
|Sarcoma, Kaposi HIV Infections||Drug: Alitretinoin|
This is a Phase 3 double-blind study. KS patients are randomized to 1 of 2 treatment arms. They receive either ALRT1057 gel or placebo for 12 weeks. If progressive disease for KS is noted before Week 12, patients are switched to the other blinded treatment arm. If a response or disease progression that has not persisted for at least 4 weeks as of Week 12 occurs, treatment on the blinded arm is continued for up to 4 additional weeks, or until response of disease progression is confirmed. After that time or after 12 weeks of treatment, open-label ALRT1057 may be received.
|Study Type :||Interventional (Clinical Trial)|
|Official Title:||Randomized Phase III Vehicle Controlled Trial of ALRT 1057 Topical Gel in Patients With AIDS-Related Kaposi's Sarcoma|
No Contacts or Locations Provided